Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001

Terese Catherine Hammond; Raymond C Lee; Bryan Oronsky; Tony R Reid; Scott Caroen; Tiffany M Juarez; Jaya Gill; Annie Heng; Santosh Kesari

doi:10.2147/IMCRJ.S389690

Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001

Int Med Case Rep J. 2022 Dec 15:15:735-738. doi: 10.2147/IMCRJ.S389690. eCollection 2022.

Authors

Terese Catherine Hammond^{1

2}, Raymond C Lee^{1

3}, Bryan Oronsky⁴, Tony R Reid⁴, Scott Caroen⁴, Tiffany M Juarez², Jaya Gill⁵, Annie Heng², Santosh Kesari^{1

2

5}

Affiliations

¹ Providence St. Johns Health Center, Santa Monica, CA, USA.
² John Wayne Cancer Institute, Santa Monica, CA, USA.
³ Cardiovascular Thoracic Institute, Keck School of Medicine of USC, Los Angeles, CA, USA.
⁴ EpicentRx, Inc., La Jolla, CA, USA.
⁵ Pacific Neuroscience Institute, Santa Monica, CA, USA.

Abstract

Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.

Keywords: ARDS; COVID-19; RRx-001; SARS-CoV-2; critical care; nitric oxide; viral diseases.

Publication types

Case Reports